What ClarityAccessHub Does
ClarityAccessHub is the patient access network purpose-built for anti-amyloid therapy delivery. The Memory Rx Toolkit operationalizes the therapy readiness, site-of-care, monitoring, and registry workflow that anti-amyloid therapy requires. CerebraLinked is the technology platform inside the toolkit that runs the four-pillar workflow.
The Model
Anti-amyloid therapy isn't a typical specialty infusion drug. The qualification workflow, the ARIA monitoring obligations, the registry requirements, and the coordination across multiple stakeholders are AD-specific. A generic hub or purchasing model doesn't operationalize these. ClarityAccessHub is purpose-built around them.
If any link in the AD chain fails, the patient doesn't get treated. ClarityAccessHub operates the infrastructure that holds the AD chain together.
ClarityAccessHub is designed to complement neurologist-directed care pathways and existing physician networks by supporting the downstream therapy readiness, site-of-care, monitoring, and operational coordination layers required for anti-amyloid therapy. We don't replace the referring neurologist — we extend their reach.
The Memory Rx Toolkit · Powered by CerebraLinked
ClarityAccessHub is the parent access network. The Memory Rx Toolkit is the AD-specific operational implementation. CerebraLinked is the technology platform inside the toolkit that operationalizes the four-pillar workflow anti-amyloid therapy requires.
What the Memory Rx Toolkit Delivers
The four-pillar workflow inside CerebraLinked is the operational engine. The Memory Rx Toolkit puts that engine to work on six AD-specific capabilities anti-amyloid manufacturers need at network scale.
Plasma biomarker screening at scale for AD — Aβ42/40, p-tau217, p-tau181, GFAP, NfL. APOE genotyping with appropriate counseling. Cognitive baseline assessment and longitudinal monitoring. Identifies candidates for current anti-amyloid therapy and the AD prevention-indication products coming behind it.
Once a patient is therapy-ready, ClarityAccessHub routes them to the nearest credentialed infusion center with appropriate ARIA monitoring capability and payer credentialing. Geographic, capacity, and quality factors built into the matching.
Multi-year patient cohorts tracked through standardized assessment. Real-world evidence on disease progression, intervention response, and biomarker trajectories. Data assets that support label expansion, pricing justification, and pipeline planning.
Patient identification and enrollment for AD prevention-indication clinical trials. Standardized AD clinical workflow across network sites. Data quality and protocol adherence at network scale. Geographic and demographic diversity supporting AD trial regulatory submission.
Adverse event tracking, outcomes monitoring, comparative effectiveness research, and Health Economics and Outcomes Research support. The data infrastructure that increasingly determines payer coverage decisions, label expansions, and post-market commitments.
Patient navigation, financial assistance coordination, treatment adherence support, and family caregiver education. The wraparound services that determine real-world treatment success and adoption at scale.
Why Now
Two convergent shifts make this the inflection point. Plasma biomarkers have crossed the operational threshold for population-scale screening. And the pipeline behind today's therapies is the deepest the neurodegenerative space has ever produced — a multi-year, multi-product opportunity the Memory Rx Toolkit is built to serve.
ClarityAccessHub operationalizes the AD-specific infrastructure that anti-amyloid therapy requires — for the patients who need it, the clinicians who treat them, and the manufacturers who develop them.
Contact ClarityAccessHub